Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer
Authors:
Open Access
- 14 January 2012
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 29 (4) , 2849-2857
Abstract
CD133 has been identified as a putative cancer stem cell (CSC) marker in various cancers including colorectal cancer. The relation between CD133 expression and biological characteristics of colorectal cancer remains to be clarified. Protein expression of CD133 was immunohistochemically evaluated in surgical specimens of 225 patients with colorectal cancer who were treated by surgery, as well as those of 78 patients with rectal cancer who received preoperative chemoradiotherapy (CRT) followed by curative resection. The correlation between CD133 expression and clinicopathological features, tumor recurrence and overall survival was analyzed in both populations. Among 225 colorectal cancers without CRT, 93 (41.3%) were positive for CD133 expression, which was enhanced in cases with advanced T stage and venous invasion. Moreover, CD133 was positive in 47 (60.3%) of 78 cases with CRT, which was significantly higher than the CD133-positive rate in non-CRT specimens (P = 0.05). Expression of CD133 was independently correlated with the histological tumor regression grade (P < 0.01). These results suggest that CD133 is not a distinctive colorectal CSC marker; expression of CD133 is suggested to be one of the key factors associated with resistance to CRT in colorectal cancer.Keywords
This publication has 45 references indexed in Scilit:
- CD133(−) Cells, Derived From a Single Human Colon Cancer Cell Line, Are More Resistant to 5-Fluorouracil (FU) Than CD133(+) Cells, Dependent on the β1-Integrin SignalingJournal of Surgical Research, 2012
- Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomasHuman Pathology, 2011
- Targeting hypoxia in cancer therapyNature Reviews Cancer, 2011
- Hypoxia in the regulation of neural stem cellsCellular and Molecular Life Sciences, 2011
- CD133+ single cell-derived progenies of colorectal cancer cell line SW480 with different invasive and metastatic potentialClinical & Experimental Metastasis, 2010
- Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancerBritish Journal of Cancer, 2010
- Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIBJournal of Translational Medicine, 2009
- Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiationProceedings of the National Academy of Sciences, 2006
- Prospective Identification of Tumorigenic Prostate Cancer Stem CellsCancer Research, 2005
- Stem Cell Regulation by the Haemopoietic Stem Cell NicheCell Cycle, 2005